As a part of this program, BioSystems International will conduct biomarker discovery using its proprietary technology platform, whilst AstraZeneca will provide clinical samples and funding.
BioSystems will retain rights to, and income from, diagnostic applications while AstraZeneca receives a non exclusive license to use the results for its internal R&D activities including exclusive rights to any new targets. BioSystems will also provide AstraZeneca with detection kits or reagents for use in their internal R&D programs.
The BioSystems technology platform permits the identification of disease or pathology-specific biomarkers within a short time frame, compatible with the constraints of drug development. Biomarkers, which make it possible to diagnose a disease, follow its progression or evaluate drug efficacy are crucial for the pharmaceutical industry.
The companies expect the collaboration to result in a significant reduction in the cost and duration of clinical trials and improve the clinical follow-up of patients.